Cohorte de supervivencia en pacientes menores de 60 años con leucemia mieloide aguda de acuerdo con la citogenética y el tratamiento de consolidación

Juan Felipe Combariza-Vallejo

doi:10.17533/udea.iatreia.v28n4a03

Authors

Juan Felipe Combariza-Vallejo Pablo Tobón Uribe Hospital

DOI:

https://doi.org/10.17533/udea.iatreia.v28n4a03

Keywords:

acute myeloid leukaemia, Colombia, hematopoietic stem cell transplantation, karyotype

Abstract

Introduction: Survival of patients with acute myeloid leukemia (AML) differs according to karyotype and the treatment they receive.

Methods: In this retrospective cohort we evaluated survival, its prognostic factors and its association with the initial karyotype in 66 patients younger than 60 years with AML, who received chemotherapy or allogeneic bone marrow transplantation.

Results: Overall survival at 2 years was 90 % in the low risk group, 61 % in the intermediate risk group and 30 % in the high risk group (p = 0.016). The following factors affected overall survival: not having reached complete remission (HR: 16.36; IC 95 %: 6.17-43.33), and not having received haematopoietic stem cell transplantation (HR: 4.76; IC 95 %: 1.36-16.69). As risk factor for relapse we found: High risk karyotype (HR: 9.18; IC 95 %: 1.22-68.56) and not having performed haematopoietic stem cell transplantation (HR: 3.06; IC 95 %: 1.14-8.18).

Conclusion: This study suggests that in Colombia the global survival of young patients with AML with intermediate or high cytogenetic risk at diagnosis may improve when they receive hematopoietic stem cell transplantation as part of the treatment.

|Abstract

= 318 veces | PDF (ESPAÑOL (ESPAÑA))

= 186 veces|

Downloads

Download data is not yet available.

Author Biography

Juan Felipe Combariza-Vallejo, Pablo Tobón Uribe Hospital

Hematologist, Pablo Tobón Uribe Hospital, Medellín, Colombia.

References

(1.) Martínez O. Epidemiología de la leucemia promielocítica aguda en el adulto. Acta Med Colomb. 2004 Jul-Sep;29(3):108-11.

(2.) Duque Sierra L, Restrepo Perdomo C, Zapata Cárdenas A, Duque Ortega J, Donado Gómez J, Mejía G. Características morfológicas, citogenéticas e inmunofenotipicas de pacientes con leucemia mieloide aguda. Medellín Colombia. CIMEL. 2006;11(2):72-7.

(3.) Díaz Correa LM, Madrid Muñoz CA, Combariza Vallejo JF, Gálvez Cárdenas KM, Olaya Colorado V, Donado Gómez JH. Supervivencia de los pacientes adultos con leucemia mieloide aguda en el departamento de Hematología del Hospital Pablo Tobón Uribe entre los años 2004 y 2010. Medicina UPB. 2012;31(2):105-12.

(4.) National Comprehensive Cancer Network [Internet]. Fort Washington: NCCN; 2014 [cited 2014 Mar 3]. Clinical Practice Guidelines in Oncology. Acute myeloid leukaemia. Version 2.2013. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

(5.) Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment

Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec;21(24):4642-9. Erratum in: JCO. 2004 Feb;22(3):576.

(6.) Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec;100(13):4325-36.

(7.) Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010 Jul;116(3):354-65.

(8.) Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996 Oct;88(8):2841-51.

(9.) Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005 Apr;103(8):1652-8.

(10.) Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007 Apr;109(9):3658-66.

(11.) Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun; 301(22):2349-61.

(12.) Burnett AK, Goldstone A, Hills RK, Milligan D, Pren-tice A, Yin J, et al. Curability of patients with acute myeloid leukemia who did not undergo transplan-tation in first remission. J Clin Oncol. 2013 Apr; 31(10):1293-301.

(13.) Santamaría CM, Chillón MC, García-Sanz R, Pérez C, Caballero MD, Ramos F, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood. 2009 Jul;114(1):148-52.

(14.) Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Rats-chiller D, Solenthaler M, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. 2005 Feb;11(4):1416-24.

IATREIA Vol 28(4) octubre-diciembre 2015387

(15.) Gorin NC, Labopin M, Pichard P, Sierra J, Fiere D, Rio B, et al. Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. Br J Haematol. 2000 Sep;110(4):887-93.

(16.) Tsimberidou AM, Stavroyianni N, Viniou N, Papaioannou M, Tiniakou M, Marinakis T, et al. Comparison of allogeneic stem cell transplantation, highdose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer. 2003 Apr;97(7):1721-31.

(17.) Nathan PC, Sung L, Crump M, Beyene J. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a metaanalysis. J Natl Cancer Inst. 2004 Jan;96(1):38-45.

(18.) Loh YS, Koh LP, Tai BC, Hwang WY, Linn YC, Goh YT, et al. Long-term follow-up of Asian patients younger than 46 years with acute myeloid leukemia in first complete remission: comparison of allogeneic vs. autologous hematopoietic stem cell transplantation. Leuk Lymphoma. 2007 Jan;48(1):72-9.

(19.) Farag SS, Ruppert AS, Mrózek K, Mayer RJ, Stone RM, Carroll AJ, et al. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. J Clin Oncol. 2005 Jan;23(3):482-93.

(20.) Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, et al. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood. 2011 Dec;118(23):6037-42.

(21.) Souto Filho JT, Portugal RD, Loureiro M, Pulcheri W, Nucci M. Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades. Braz J Med Biol Res. 2011 Jul;44(7):660-5.

(22.) Bueno ND, Dulley FL, Saboya R, Amigo Filho JU, Coracin FL, Chamone Dde A. Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission. Rev Bras Hematol Hemoter. 2011;33(3):179-84.

(23.) Lamego RM, Clementino NCD, Costa ALB, Oliveira MJM, Bittencourt H. Allogeneic hematopoietic stem cells transplantation in acute leukemia: ten years of experience in the Hospital das Clínicas – UFMG. Rev Bras Hematol Hemoter. 2010;32(2):108-15.